Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

May 29, 2026

Vol.52 No.21

In Brief

Charles Rudin named cancer center director at MSK

Charles Rudin was appointed director of Memorial Sloan Kettering Cancer Center, effective June 1.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

Physicians and researchers at Winship Cancer Institute of Emory University announced they have administered the first investigational in vivo CAR-T cell therapy in the United States for relapsed and refractory multiple myeloma.

May 22, 2026

Vol.52 No.20

Clinical Roundup

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

Drugs & Targets

Sartorius launches platform to boost efficiency in cell therapy production

Sartorius is launching an integrated system for the production and quality control of autologous cell therapies. The modular Eveo Cell Therapy Platform is designed to address structural manufacturing bottlenecks that limit scalability and patient access to transformative treatments such as CAR T therapies.

March 20, 2026

Vol.52 No.11

In Brief

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Lonny Yarmus was appointed head of the Division of Subspecialty Medicine in the Department of Medicine at Memorial Sloan Kettering Cancer Center. A physician-scientist and internationally recognized leader in interventional pulmonology and procedural innovation, Yarmus is widely known for his expertise in minimally invasive diagnostics and therapeutics, outcomes research, and multidisciplinary program development.

March 13, 2026

Vol.52 No.10

Michel Sadelain, Carl June receive 2024 Breakthrough Prize in Life Sciences

YOU MAY BE INTERESTED IN

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Charles Rudin named cancer center director at MSK

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

Sartorius launches platform to boost efficiency in cell therapy production

Lonny Yarmus named head of the Division of Subspecialty Medicine at MSK

Renew today!

Subscriber content

Never miss an issue!

Login